Nurse Practitioner Program year 2025 Reported 2023–2025 Source: CMS Open Payments, 2026 publication

Julilyn Brown

Nurse Practitioner Zanesville, OH Nurse Practitioner

NPI 1003508250 CMS profile 11532535

930 Bethesda Dr, Zanesville, OH 43701

Open in the dashboard

General payments

$5,282

293 records reported · program years 2023–2025

Research payments

$0

Paid to them · None reported · program years 2023–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Julilyn Brown of Zanesville, OH is reported in the CMS Open Payments database as having received $5,282 across 293 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,330 129
2024 General $1,833 97
2023 General $1,119 67

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Julilyn Brown
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Julilyn Brown were reported at $2,330. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Julilyn Brown Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $0 $135 $40–$426 $132
2022 $0 $152 $48–$470 $149
2023 $1,119 $166 $54–$529 $160
2024 $1,833 $173 $55–$556 $164
2025 $2,330 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2023–2025
  1. E.R. Squibb & Sons, L.L.C. $1,016 41 payments
  2. AbbVie, Inc. $735 56 payments
  3. ITI, Inc. $679 49 payments
  4. Axsome Therapeutics, Inc. $628 30 payments
  5. Lundbeck LLC $391 20 payments
  6. Otsuka America Pharmaceutical, Inc. $379 19 payments
  7. Neurocrine Biosciences, Inc. $239 12 payments
  8. Takeda Pharmaceuticals U.S.A., Inc. $228 12 payments
  9. Teva Pharmaceuticals USA, Inc. $214 11 payments
  10. Corium, Inc. $168 11 payments
  11. Other $605 32 payments

Every payment, record by record

What the payments were for General payments · program years 2023–2025
  1. Food and Beverage $5,270 292 payments
  2. Education $12 1 payment
Products named General payments · program years 2023–2025
  1. COBENFY $850 37 payments
  2. Auvelity $628 30 payments
  3. REXULTI Psychiatry $391 20 payments
  4. VRAYLAR Neuroscience $383 34 payments
  5. CAPLYTA Psychiatry $359 21 payments
  6. VRAYLAR Neuroscience $353 22 payments
  7. REXULTI Psychiatry $344 17 payments
  8. CAPLYTA Psychiatry $320 28 payments
  9. INGREZZA $239 12 payments
  10. TRINTELLIX $228 12 payments
  11. Other $1,597 82 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 29 drugs

Part D claims

809

Median for Nurse Practitioner: 389

Drug cost

$49,218

Median for Nurse Practitioner: $21,885

Branded share of claims

25.1%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Vraylar Cariprazine Hcl Brand 21 $29,595
Lurasidone Hcl Generic 32 $10,170
Paliperidone Er Paliperidone Brand 16 $1,905
Bupropion Xl Bupropion Hcl Brand 39 $1,290
Olanzapine Generic 27 $656
Buprenorphine-Naloxone Buprenorphine Hcl/Naloxone Hcl Brand 23 $636
Lamotrigine Generic 82 $608
Duloxetine Hcl Generic 18 $493
Quetiapine Fumarate Generic 38 $463
Dextroamphetamine-Amphetamine Dextroamphetamine/Amphetamine Brand 26 $425

The 10 drugs with the highest cost, of 29 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 5 billing codes

Paid by Medicare

$3,287

Medicare's payments for the services billed

Medicare patients

17

Average age 58

Services billed

50

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 22 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VRAYLAR
  • AbbVie, Inc. $332
$332 21 —
REXULTI
  • Lundbeck LLC $140
  • Otsuka America Pharmaceutical, Inc. $123
$263 — —
Auvelity
  • Axsome Therapeutics, Inc. $248
$248 — —
CAPLYTA
  • ITI, Inc. $177
$177 — —
COBENFY
  • E.R. Squibb & Sons, L.L.C. $166
$166 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 22 in the dashboard with a free account

Records

293 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record